Featured Research

from universities, journals, and other organizations

Engineered antibodies directed against a promising therapeutic target on ovarian cancer cells

Date:
June 30, 2010
Source:
Fox Chase Cancer Center
Summary:
Stealthy and stubborn, ovarian cancer is a particularly vexing malignancy, difficult to diagnose in early stages and difficult to treat once it progresses further. However, research is now focusing on one of the most promising new approaches to dealing with the disease -- using engineered antibodies to target tumor cells while leaving healthy cells intact.

Stealthy and stubborn, ovarian cancer is a particularly vexing malignancy, difficult to diagnose in early stages and difficult to treat once it progresses further. However, research at Fox Chase Cancer Center is now focusing on one of the most promising new approaches to dealing with the disease--using engineered antibodies to target tumor cells while leaving healthy cells intact.

Gregory Adams, Ph.D., co-leader of the Developmental Therapeutics Program at Fox Chase Cancer Center, and colleagues recently isolated a small, antibody-like molecule called GS45, which is capable of zeroing in on a sort of red flag that distinguishes ovarian cancer cells from normal cells. Tatiana Karakasheva, M.S., a graduate student in Adams laboratory, will present the findings at the 2010 annual meeting of the American Association for Cancer Research.

The GS45 molecule targets a receptor called the Mόllerian Inhibiting Substance Type II Receptor (MISIIR), which is scarce in normal tissue, but more abundantly present on the surface of human ovarian cancer cells.

"A general problem with targeted therapies is that many of the targets found on cancer cells are also found on normal cells," says Karakasheva. "When you direct cell-killing drugs at those targets, you get side effects. The great thing about our target is that in healthy tissue, it's primarily restricted to the reproductive system, and its expression dramatically increases in ovarian cancer."

"But attractive as MISIIR is as a target, finding antibodies that will home in and bind to it has been a challenge," Adams says.

Using a method called combinatorial single-chain Fv phage display, in which human antibody fragments are expressed and selected on the surface of viruses that infect bacteria, Karakasheva and Adams managed to isolate a group of good candidates, including GS45.

They have just completed engineering the fragments into full-size human antibodies that will be used in experiments with a mouse model of human ovarian cancer. The first step will be to demonstrate that GS45 actually does target only ovarian cancer cells, not healthy tissue. Then, the researchers plan to attach a cell-killing drug to the antibody, to explore its potential in cancer treatment.

"Because mouse and human MISIIR are almost identical, whatever the mouse experiments reveal about targeting and toxicity is likely to apply to humans," Adams says. "This puts us in a powerful position to move this work forward through pre-clinical studies to a point where we'll know if it's worth taking to clinical trials."

In addition to Adams and Karakasheva, the paper's authors are scientific associate Heidi Simmons, B.S., postdoctoral trainee Stephen Rudnick, Ph.D., and assistant professor Matthew Robinson, Ph.D.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Engineered antibodies directed against a promising therapeutic target on ovarian cancer cells." ScienceDaily. ScienceDaily, 30 June 2010. <www.sciencedaily.com/releases/2010/04/100419150824.htm>.
Fox Chase Cancer Center. (2010, June 30). Engineered antibodies directed against a promising therapeutic target on ovarian cancer cells. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2010/04/100419150824.htm
Fox Chase Cancer Center. "Engineered antibodies directed against a promising therapeutic target on ovarian cancer cells." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419150824.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) — In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) — A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) — The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) — President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins